Baya Nikolas A, Erdem Ilknur Sur, Venkatesh Samvida S, Reibe Saskia, Charles Philip D, Navarro-Guerrero Elena, Hill Barney, Lassen Frederik Heymann, Claussnitzer Melina, Palmer Duncan S, Lindgren Cecilia M
medRxiv. 2025 Mar 14:2024.09.19.24313913. doi: 10.1101/2024.09.19.24313913.
Overall adiposity and body fat distribution are heritable traits associated with altered risk of cardiometabolic disease and mortality. Performing rare variant (minor allele frequency<1%) association testing using exome-sequencing data from 402,375 participants in the UK Biobank (UKB) for nine overall and tissue-specific fat distribution traits, we identified 19 genes where putatively damaging rare variation associated with at least one trait (Bonferroni-adjusted <1.58×10 ) and 50 additional genes at FDR≤1% ( ≤4.37×10 ). These 69 genes exhibited significantly higher (one-sided -test =3.58×10 ) common variant prioritisation scores than genes not significantly enriched for rare putatively damaging variation, with evidence of monotonic allelic series (dose-response relationships) among ultra-rare variants (minor allele count≤10) in 22 genes. Combining rare and common variation evidence, allelic series and longitudinal analysis, we selected 14 genes for CRISPR knockdown in human white adipose tissue cell lines. In three previously uncharacterised target genes, knockdown increased (two-sided -test <0.05) lipid accumulation, a cellular phenotype relevant for fat mass traits, compared to Cas9-empty negative controls: (fold change [FC]=1.72, =0.0028), (FC=1.35, =0.0096), and (FC=1.39, =0.0157); furthermore, knockdown of (FC=0.25, =5.52×10 ) and (FC=0.51, =1.91×10 ) resulted in reduced lipid accumulation. Integrating across population-based genetic and functional evidence, we highlight therapeutic avenues for altering obesity and body fat distribution by modulating lipid accumulation.
总体肥胖程度和体脂分布是可遗传的性状,与心血管代谢疾病风险和死亡率的改变相关。利用英国生物银行(UKB)中402375名参与者的外显子测序数据,对9种总体和组织特异性脂肪分布性状进行罕见变异(次要等位基因频率<1%)关联测试,我们鉴定出19个基因,其中推定有害的罕见变异与至少一种性状相关(Bonferroni校正P<1.58×10⁻⁵),另外还有50个基因在FDR≤1%(P≤4.37×10⁻³)时相关。这69个基因表现出比未显著富集罕见推定有害变异的基因显著更高(单侧t检验P = 3.58×10⁻⁴)的常见变异优先评分,在22个基因的超罕见变异(次要等位基因计数≤10)中有单调等位基因系列(剂量反应关系)的证据。结合罕见和常见变异证据、等位基因系列和纵向分析,我们选择了14个基因在人白色脂肪组织细胞系中进行CRISPR敲低。在三个先前未表征的靶基因中,与空载体Cas9阴性对照相比,敲低增加了(双侧t检验P<0.05)脂质积累,这是一种与脂肪量性状相关的细胞表型:TMEM18(倍数变化[FC]=1.72,P = 0.0028)、ANKRD55(FC=1.35,P = 0.0096)和PRKD1(FC=1.39,P = 0.0157);此外,敲低ACOT11(FC=0.25,P = 5.52×10⁻⁴)和ZC3H10(FC=0.51,P = 1.91×10⁻³)导致脂质积累减少。整合基于人群的遗传和功能证据,我们强调了通过调节脂质积累来改变肥胖和体脂分布的治疗途径。